Urinary Leukotriene E4 as a Biomarker of Disease Burden in Aspirin‐Exacerbated Respiratory Disease: A Retrospective Cohort Study

Key Points

• To evaluate the role of urinary leukotriene E4 as a biomarker in assessing disease burden in aspirin-exacerbated respiratory disease.
• Conducted a retrospective cohort study
• Analyzed urinary leukotriene E4 levels in patients with aspirin-exacerbated respiratory disease
• Compared disease burden measures with leukotriene E4 levels
• Urinary leukotriene E4 levels correlated with higher disease burden
• Patients with elevated leukotriene E4 exhibited more severe respiratory symptoms
• Findings suggest urinary leukotriene E4 can serve as a reliable biomarker for monitoring disease severity